Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils
NCT ID: NCT06495827
Last Updated: 2024-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
653 participants
OBSERVATIONAL
2010-07-31
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
NCT03532711
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
NCT03008499
Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy
NCT00918827
Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer
NCT01929499
CTC vs Radiography as the Evidence of Recurrence in Colorectal Cancer Patients
NCT04917289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
response cohort
CRC patients with response status after chemotherapy
No different intenvention
No different intenvention
resistance cohort
CRC patients with resistance status after chemotherapy
No different intenvention
No different intenvention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No different intenvention
No different intenvention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The Eastern Cancer Collaborative Organization (ECOG) has a physical fitness score of 0 or 1.
3. The expected survival period is ≥ 3 months.
5\. Subjects diagnosed with metastatic colorectal adenocarcinoma by histology or cytology.
6\. Colorectal cancer patients who have not received systematic anti-tumor therapy in the past.
Exclusion Criteria
2. Simultaneously enroll in another clinical study, unless it is an observational, non-interference clinical study or a follow-up period of an intervention study.
3. Received systematic anti-tumor therapy (chemotherapy) within 3 weeks prior to the first administration
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xu jianmin
Head of colorectal surgery department, Principal Investigator, Clinical Professor, Zhongshan Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TANs for CT response in CRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.